NEW YORK – Promega and QuantumCyte announced on Tuesday an agreement to jointly market a clinical lab workflow comprising QuantumCyte's QCPrecise automated microdissection platform alongside Promega's Maxwell CSC and ReliaPrep nucleic acid purification platforms.
Financial details of the agreement were not disclosed.
The combined platforms are meant to help clinical labs optimize their workflow efficiency.
The QCPrecise platform "increases cellular nucleic acid purity from solid tissue biopsies for downstream multiomic applications," QuantumCyte CSO John Butler said in a statement. Combining it with the Maxwell CSC System and ReliaPrep kitsresults in "a complete workflow that produces high purity nucleic acid" for commercial, research, and pharma applications, Butler added.
The companies said in a statement that they would be prepared to answer questions about the new workflow at the Association for Molecular Pathology annual meeting next week in Vancouver, British Columbia.
At last year's AMP meeting, QuantumCyte announced a partnership with the Mayo Clinic to develop a colorectal cancer prognostic assay using QPrecise.
Also last year, Promega inked a deal to develop and commercialize a microsatellite instability companion diagnostic IVD kit with GlaxoSmithKline.